...
首页> 外文期刊>Journal of experimental & clinical cancer research : >Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1
【24h】

Inhibition of COX-2, mPGES-1 and CYP4A by isoliquiritigenin blocks the angiogenic Akt signaling in glioma through ceRNA effect of miR-194-5p and lncRNA NEAT1

机译:异寡糖原蛋白对COX-2,mPGES-1和CYP4A的抑制作用通过miR-194-5p和lncRNA NEAT1的ceRNA效应阻断神经胶质瘤中的血管生成Akt信号传导

获取原文
           

摘要

Arachidonic acid (AA) metabolic enzymes including cyclooxygenase-2 (COX-2), microsomal prostaglandin E synthase-1 (mPGES-1) and cytochrome P450 (CYP) 4A11 play important roles in glioma angiogenesis. Thus, there is an urgent need to identify the underlying mechanisms and develop strategies to overcome them. A homology model of human CYP4A11 was constructed using SYBYL-X 2.0. Structure-based virtual screening against COX-2, mPGES-1 and CYP4A11was performed using the Surflex-Dock of the SYBYL suite. The candidates were further evaluated their antiangiogenic activities in a zebrafish embryo and rabbit corneal angiogenesis model. Laser doppler analysis was used to measure tumor perfusion. The expression of CD31 and α-SMA was measured by immunofluorescence. Western blot was used to measure the expression of HIF-1, Akt and p-Akt. The gene expression of FGF-2, G-CSF, PDGF, TGF-β, Tie-2, VEGF, lncRNA NEAT1 and miR-194-5p were determined using qPCR. The production of FGF-2, TGF-β and VEGF were analyzed using ELISA. Bioinformatic analysis and luciferase reporter assays confirmed the interaction between lncRNA NEAT1 and miR-194-5p. The nearly 36,043 compounds from the Traditional Chinese Medicine (TCM) database were screened against COX-2, mPGES-1 and CYP4A11 3D models, and the 17 top flavonoids were identified. In zebrafish screening, isoliquiritigenin (ISL) exhibited the most potent antiangiogenic activities with the EC50 values of 5.9?μM. Conversely, the antiangiogenic effects of ISL in the zebrafish and rabbit corneal models were partly reversed by 20-hydroxyeicosatetraenoic acid (20-HETE) or prostaglandin E2 (PGE2). ISL normalized glioma vasculature and improved the efficacy of temozolomide therapy in the rat C6 glioma model. Inhibition of COX-2, mPGES-1 and CYP4A by ISL decreased FGF-2, TGF-β and VEGF production in the C6 and U87 glioma cells with p-Akt downregulation, which was reversed by Akt overexpression. Furthermore, ISL downregulated lncRNA NEAT1 but upregulated miR-194-5p in the U87 glioma cell. Importantly, lncRNA NEAT1 overexpression reversed ISL-mediated increase in miR-194-5p expression, and thereby attenuated FGF-2, TGF-β and VEGF production. Reprogramming COX-2, mPGES-1 and CYP4A mediated-AA metabolism in glioma by flavonoid ISL inhibits the angiogenic Akt- FGF-2/TGF-β/VEGF signaling through ceRNA effect of miR-194-5p and lncRNA NEAT1, and may serve as a novel therapeutic strategy for human glioma.
机译:花生四烯酸(AA)代谢酶包括环氧合酶2(COX-2),微粒体前列腺素E合酶1(mPGES-1)和细胞色素P450(CYP)4A11在神经胶质瘤血管生成中起重要作用。因此,迫切需要确定潜在的机制并制定克服这些机制的策略。使用CYBYL-X 2.0构建了人CYP4A11的同源性模型。使用SYBYL套件的Surflex-Dock对COX-2,mPGES-1和CYP4A11进行了基于结构的虚拟筛选。在斑马鱼胚胎和兔角膜血管生成模型中进一步评估了候选人的抗血管生成活性。激光多普勒分析用于测量肿瘤灌注。通过免疫荧光测定CD31和α-SMA的表达。免疫印迹用于测量HIF-1,Akt和p-Akt的表达。使用qPCR测定FGF-2,G-CSF,PDGF,TGF-β,Tie-2,VEGF,lncRNA NEAT1和miR-194-5p的基因表达。使用ELISA分析了FGF-2,TGF-β和VEGF的产生。生物信息学分析和荧光素酶报告基因分析证实了lncRNA NEAT1与miR-194-5p之间的相互作用。针对COX-2,mPGES-1和CYP4A11 3D模型筛选了来自中药(TCM)数据库的近36043种化合物,并鉴定出17种顶级黄酮类化合物。在斑马鱼的筛查中,异quiligenigenin(ISL)表现出最强的抗血管生成活性,EC50值为5.9?M。相反,ISL在斑马鱼和兔角膜模型中的抗血管生成作用被20-羟基二十碳四烯酸(20-HETE)或前列腺素E2(PGE2)所部分逆转。 ISL在大鼠C6神经胶质瘤模型中使神经胶质瘤血管系统正常化,并改善了替莫唑胺治疗的疗效。 ISL对COX-2,mPGES-1和CYP4A的抑制作用可降低C6和U87神经胶质瘤细胞中FGF-2,TGF-β和VEGF的生成,并下调p-Akt,而Akt过表达则逆转了这种变化。此外,ISL在U87胶质瘤细胞中下调了lncRNA NEAT1,但上调了miR-194-5p。重要的是,lncRNA NEAT1过表达逆转了ISL介导的miR-194-5p表达增加,从而减弱了FGF-2,TGF-β和VEGF的产生。类黄酮ISL对神经胶质瘤中COX-2,mPGES-1和CYP4A介导的AA代谢进行重新编程可通过miR-194-5p和lncRNA NEAT1的ceRNA效应抑制血管生成的Akt-FGF-2 /TGF-β/ VEGF信号传导,并可能起到作用作为人类神经胶质瘤的新型治疗策略。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号